PHVS Pharvaris N.V.
$39.71▲ +4.45%
Healthcare
Other
Volume 552.4K
Avg Volume (10D) 1.31M
Key Metrics & Fundamentals
Market Cap
$2.79B
P/E Ratio
–
Div Yield
–%
52W Range
20.65 - 43.25
% vs 50 MA
8.43%
% vs 200 MA
27.58%
RSI-14
62.2
MACD Histogram
+0.1500
Beta (1Y vs SPY)
0.91
Free Cash Flow
-$37.83M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$52.25M
COGS
–
Operating Exp
$50.79M
Operating Income
-$50.79M
EBIT
-$50.79M
Pretax Income
-$47.24M
Net Income
-$47.84M
EPS (Diluted)
-0.70
Price & Volume History
Loading chart…
Recent News
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Insider Monkey · Sep 10, 2026 11:25 PM
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
Stocktwits · Sep 10, 2026 3:52 PM
BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
MT Newswires · Sep 10, 2026 3:42 PM
Pharvaris Insider Sold Shares Worth $610,134, According to a Recent SEC Filing
MT Newswires · Sep 9, 2026 3:22 PM
Pharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC Says
MT Newswires · Sep 9, 2026 3:18 PM
Pharvaris charts approval course for swelling disorder drug on Phase III win
Clinical Trials Arena · Sep 9, 2026 11:33 AM
RBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative Risk
MT Newswires · Sep 9, 2026 10:57 AM
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Stocktwits · Sep 8, 2026 11:24 PM
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
Investor's Business Daily · Sep 8, 2026 8:24 PM
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
Stocktwits · Sep 8, 2026 5:53 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See PHVS's money flow as a full page
Social Sentiment
No Reddit posts found for PHVS.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.